Literature DB >> 23391677

Primary care considerations of the pharmacokinetics and clinical use of extended-release opioids in treating patients with chronic noncancer pain.

Bruce Nicholson1.   

Abstract

Extended-release (ER) opioid analgesics are associated with prolonged analgesia and greater stability in pain relief compared with immediate-release formulations. Due to the pharmacokinetic (PK) characteristics of ER opioids and additional clinical advantages, the use of ER opioids for patients with moderate-to-severe chronic noncancer pain has increased. Primary care physicians are the major prescribers of opioids and require an in-depth understanding of the risks and benefits of opioid treatment in pain management. With appropriate knowledge of PK profiles and clinical outcomes of commonly prescribed ER opioids, primary care physicians can safely and effectively manage this patient population. In addition, the development of ER opioids with abuse-deterrent features marks an important milestone in potentially reducing abuse and may be factored into the clinical decision-making process. This article provides a comprehensive review of the PK and clinical effects of ER opioids and discusses novel ER opioid formulations that may limit abuse potential.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23391677     DOI: 10.3810/pgm.2013.01.2627

Source DB:  PubMed          Journal:  Postgrad Med        ISSN: 0032-5481            Impact factor:   3.840


  2 in total

1.  Clinical Pharmacokinetic Characteristics of Cebranopadol, a Novel First-in-Class Analgesic.

Authors:  Elke Kleideiter; Chiara Piana; Shaonan Wang; Robert Nemeth; Michael Gautrois
Journal:  Clin Pharmacokinet       Date:  2018-01       Impact factor: 6.447

2.  Preclinical and Clinical Pharmacology of Hydrocodone for Chronic Pain: A Mini Review.

Authors:  Luigi Cardia; Gioacchino Calapai; Domenico Quattrone; Cristina Mondello; Vincenzo Arcoraci; Fabrizio Calapai; Carmen Mannucci; Epifanio Mondello
Journal:  Front Pharmacol       Date:  2018-10-01       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.